부산대학교 도서관

The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata. Https://doi.org/10.1093/bjd/ljad118 Dear Editor, Alopecia areata (AA) is a relapsing and remitting hair-loss disorder that produces significant psychological and socioeconomic impairment, and may contribute to suicidality.[1] Baricitinib is an oral selective reversible inhibitor of Janus kinase (JAK) 1 and JAK2 that has recently received US Food and Drugs Administration (FDA) approval for severe AA in adults (aged >= 18 years). Demographic and clinical characteristics, family history, previous treatments, baseline Severity of Alopecia Tool (SALT) score, changes in SALT score, and details of patient-reported and biochemical adverse events were collected. [Extracted from the article]